Autoinjectors Market
Description
Autoinjectors Market Summary
The global autoinjectors market size was estimated at USD 10.2 billion in 2025 and is projected to reach USD 28.4 billion by 2033, growing at a CAGR of 13.8% from 2026 to 2033. The auto injectors market is driven by the increasing prevalence of chronic diseases such as diabetes and anaphylaxis, necessitating user-friendly medication delivery systems.
Rising awareness of self-administration benefits, advancements in biologics, and technological innovations enhance safety and ease of use. Supportive government policies, increased healthcare expenditure, and demand for minimally invasive devices further boost market growth.
Autoinjectors are preferred over conventional devices due to their efficient and enhanced drug delivery capabilities and compatibility with new formulations. They offer several benefits, including reduced needle phobia and anxiety, decreased risk of needle stick injuries, consistent dose accuracy, and improved efficacy, which drives their adoption in diverse patient pools. Similarly, the increasing availability and access to user friendly autoinjectors which can be administered at home is further increasing their adoption. For instance, in May 2024, the FDA approved the Benlysta autoinjector for at-home use in children aged 5 years and older with lupus. This approval aims to improve treatment accessibility and convenience, allowing caregivers to administer the medication outside of clinical settings. The autoinjector is designed to enhance patient adherence to therapy, which is crucial for managing lupus effectively.
Moreover, conditions such as rheumatoid arthritis, multiple sclerosis, and anaphylaxis require frequent injections, making auto-injectors a preferred option due to their ease of use, accuracy, and patient compliance benefits. The shift towards biologics and biosimilars, particularly in therapeutic areas such as immunology and oncology, is further fueling demand. Biopharmaceutical companies are actively investing in patient-centric drug delivery technologies, ensuring that auto-injectors are compatible with a broader range of formulations. In addition, the expansion of home-based treatment options and self-administration preferences has further strengthened the adoption of these devices, reducing the burden on healthcare facilities while improving patient outcomes.
Global Autoinjectors Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global autoinjectors market report on the basis of product, indication, end-use, and region:
The global autoinjectors market size was estimated at USD 10.2 billion in 2025 and is projected to reach USD 28.4 billion by 2033, growing at a CAGR of 13.8% from 2026 to 2033. The auto injectors market is driven by the increasing prevalence of chronic diseases such as diabetes and anaphylaxis, necessitating user-friendly medication delivery systems.
Rising awareness of self-administration benefits, advancements in biologics, and technological innovations enhance safety and ease of use. Supportive government policies, increased healthcare expenditure, and demand for minimally invasive devices further boost market growth.
Autoinjectors are preferred over conventional devices due to their efficient and enhanced drug delivery capabilities and compatibility with new formulations. They offer several benefits, including reduced needle phobia and anxiety, decreased risk of needle stick injuries, consistent dose accuracy, and improved efficacy, which drives their adoption in diverse patient pools. Similarly, the increasing availability and access to user friendly autoinjectors which can be administered at home is further increasing their adoption. For instance, in May 2024, the FDA approved the Benlysta autoinjector for at-home use in children aged 5 years and older with lupus. This approval aims to improve treatment accessibility and convenience, allowing caregivers to administer the medication outside of clinical settings. The autoinjector is designed to enhance patient adherence to therapy, which is crucial for managing lupus effectively.
Moreover, conditions such as rheumatoid arthritis, multiple sclerosis, and anaphylaxis require frequent injections, making auto-injectors a preferred option due to their ease of use, accuracy, and patient compliance benefits. The shift towards biologics and biosimilars, particularly in therapeutic areas such as immunology and oncology, is further fueling demand. Biopharmaceutical companies are actively investing in patient-centric drug delivery technologies, ensuring that auto-injectors are compatible with a broader range of formulations. In addition, the expansion of home-based treatment options and self-administration preferences has further strengthened the adoption of these devices, reducing the burden on healthcare facilities while improving patient outcomes.
Global Autoinjectors Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global autoinjectors market report on the basis of product, indication, end-use, and region:
- Product Outlook (Revenue, USD Million, 2021 - 2033)
- Disposable auto-injectors
- Reusable auto-injectors
- Prefilled
- Empty
- Indication Outlook (Revenue, USD Million, 2021 - 2033)
- Rheumatoid Arthritis
- Multiple Sclerosis
- Diabetes
- Anaphylaxis
- Other Therapies
- End-use Outlook (Revenue, USD Million, 2021 - 2033)
- Homecare Settings
- Hospitals & Clinics
- Ambulatory Surgical Centers
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
160 Pages
- Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.1. Segment Definitions
- 1.1.1. Product
- 1.1.2. Indication
- 1.1.3. End Use
- 1.1.4. Regional scope
- 1.1.5. Estimates and forecasts timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR’s internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.3.5.1. Data for primary interviews in North America
- 1.3.5.2. Data for primary interviews in Europe
- 1.3.5.3. Data for primary interviews in Asia Pacific
- 1.3.5.4. Data for primary interviews in Latin America
- 1.3.5.5. Data for Primary interviews in MEA
- 1.4. Information or Data Analysis
- 1.4.1. Data analysis models
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.6.1. Commodity flow analysis (Model 1)
- 1.6.2. Approach 1: Commodity flow approach
- 1.6.3. Volume price analysis (Model 2)
- 1.6.4. Approach 2: Volume price analysis
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
- Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Product outlook
- 2.2.2. Indication outlook
- 2.2.3. End Use outlook
- 2.3. Regional outlook
- 2.4. Competitive Insights
- Chapter 3. Autoinjectors Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.1.1. Growing prevalence of targeted therapies
- 3.2.1.2. Increase in the incidence of anaphylactic shock
- 3.2.1.3. Patients’ preference to choose self-administration of injections
- 3.2.2. Market Restraint Analysis
- 3.2.2.1. Availability of its substitute products like general injections and oral tablets
- 3.3. Auto-Injectors Market Analysis Tools
- 3.3.1. Industry Analysis - Porter’s
- 3.3.1.1. Bargaining power of suppliers
- 3.3.1.2. Bargaining power of buyers
- 3.3.1.3. Threat of substitutes
- 3.3.1.4. Threat of new entrants
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Economic landscape
- 3.3.2.3. Social landscape
- 3.3.2.4. Technological landscape
- 3.3.2.5. Environmental landscape
- 3.3.2.6. Legal landscape
- Chapter 4. Autoinjectors Market: Product Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Autoinjectors Market: Product Movement Analysis
- 4.3. AutoinjectorsMarket by Product Outlook (USD Million)
- 4.4. Market Size & Forecasts and Trend Analyses, 2021 - 2033 for the following
- 4.5. Disposable Auto-Injectors
- 4.5.1. Disposable Autoinjectors Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6. Reusable Auto-Injectors
- 4.6.1. Reusable Autoinjectors Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6.1.1. Prefilled Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6.1.1.1. Prefilled Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6.1.2. Empty Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 4.6.1.2.1. Empty Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 5. Autoinjectors Market: Indication Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Autoinjectors Market: Indication Movement Analysis
- 5.3. AutoinjectorsMarket by Indication Outlook (USD Million)
- 5.4. Market Size & Forecasts and Trend Analyses, 2021 - 2033 for the following
- 5.5. Rheumatoid Arthritis
- 5.5.1. Rheumatoid Arthritis Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.6. Multiple Sclerosis
- 5.6.1. Multiple Sclerosis Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.7. Diabetes
- 5.7.1. Diabetes Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.8. Anaphylaxis
- 5.8.1. Anaphylaxis Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 5.9. Other Therapies
- 5.9.1. Other Therapies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 6. Autoinjectors Market: End Use Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Autoinjectors Market: End Use Movement Analysis
- 6.3. Autoinjectors Market by End Use Outlook (USD Million)
- 6.4. Market Size & Forecasts and Trend Analyses, 2021 - 2033 for the following
- 6.5. Homecare Settings
- 6.5.1. Homecare Settings Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.6. Hospitals & Clinics
- 6.6.1. Hospitals & Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- 6.7. Ambulatory Surgical Centers
- 6.7.1. Ambulatory Surgical Centers Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 7. Autoinjectors Market: Regional Estimates & Trend Analysis
- 7.1. Regional Dashboard
- 7.2. Regional Autoinjectors Market movement analysis
- 7.3. Autoinjectors Market: Regional Estimates & Trend Analysis by Product, Indication & End Use
- 7.4. Market Size & Forecasts and Trend Analyses, 2021 - 2033 for the following
- 7.5. North America
- 7.5.1. North America Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.2. U.S.
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Competitive Scenario
- 7.5.2.3. Regulatory Framework
- 7.5.2.4. Reimbursement scenario
- 7.5.2.5. U.S. Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.3. Canada
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Competitive Scenario
- 7.5.3.3. Regulatory Framework
- 7.5.3.4. Reimbursement scenario
- 7.5.3.5. Canada Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.4. Mexico
- 7.5.4.1. Key Country Dynamics
- 7.5.4.2. Competitive Scenario
- 7.5.4.3. Regulatory Framework
- 7.5.4.4. Reimbursement scenario
- 7.5.4.5. Mexico Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.5. Europe
- 7.5.6. Europe Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.7. UK
- 7.5.7.1. Key Country Dynamics
- 7.5.7.2. Competitive Scenario
- 7.5.7.3. Regulatory Framework
- 7.5.7.4. Reimbursement scenario
- 7.5.7.5. UK Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.8. Germany
- 7.5.8.1. Key Country Dynamics
- 7.5.8.2. Competitive Scenario
- 7.5.8.3. Regulatory Framework
- 7.5.8.4. Reimbursement scenario
- 7.5.8.5. Germany Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.9. France
- 7.5.9.1. Key Country Dynamics
- 7.5.9.2. Competitive Scenario
- 7.5.9.3. Regulatory Framework
- 7.5.9.4. Reimbursement scenario
- 7.5.9.5. France Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.10. Italy
- 7.5.10.1. Key Country Dynamics
- 7.5.10.2. Competitive Scenario
- 7.5.10.3. Regulatory Framework
- 7.5.10.4. Reimbursement scenario
- 7.5.10.5. Italy Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.11. Spain
- 7.5.11.1. Key Country Dynamics
- 7.5.11.2. Competitive Scenario
- 7.5.11.3. Regulatory Framework
- 7.5.11.4. Reimbursement scenario
- 7.5.11.5. Spain Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.12. Denmark
- 7.5.12.1. Key Country Dynamics
- 7.5.12.2. Competitive Scenario
- 7.5.12.3. Regulatory Framework
- 7.5.12.4. Reimbursement scenario
- 7.5.12.5. Denmark Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.13. Sweden
- 7.5.13.1. Key Country Dynamics
- 7.5.13.2. Competitive Scenario
- 7.5.13.3. Regulatory Framework
- 7.5.13.4. Reimbursement scenario
- 7.5.13.5. Sweden Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.14. Norway
- 7.5.14.1. Key Country Dynamics
- 7.5.14.2. Competitive Scenario
- 7.5.14.3. Regulatory Framework
- 7.5.14.4. Reimbursement scenario
- 7.5.14.5. Norway Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6. Asia Pacific
- 7.6.1. Asia Pacific Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.2. Japan
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Competitive Scenario
- 7.6.2.3. Regulatory Framework
- 7.6.2.4. Reimbursement scenario
- 7.6.2.5. Japan Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.3. China
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Competitive Scenario
- 7.6.3.3. Regulatory Framework
- 7.6.3.4. Reimbursement scenario
- 7.6.3.5. China Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.4. India
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Competitive Scenario
- 7.6.4.3. Regulatory Framework
- 7.6.4.4. Reimbursement scenario
- 7.6.4.5. India Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.5. South Korea
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Competitive Scenario
- 7.6.5.3. Regulatory Framework
- 7.6.5.4. Reimbursement scenario
- 7.6.5.5. South Korea Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.6. Australia
- 7.6.6.1. Key Country Dynamics
- 7.6.6.2. Competitive Scenario
- 7.6.6.3. Regulatory Framework
- 7.6.6.4. Reimbursement scenario
- 7.6.6.5. Australia Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.7. Thailand
- 7.6.7.1. Key Country Dynamics
- 7.6.7.2. Competitive Scenario
- 7.6.7.3. Regulatory Framework
- 7.6.7.4. Reimbursement scenario
- 7.6.7.5. Thailand Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7. Latin America
- 7.7.1. Latin America Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.2. Brazil
- 7.7.2.1. Key Country Dynamics
- 7.7.2.2. Competitive Scenario
- 7.7.2.3. Regulatory Framework
- 7.7.2.4. Reimbursement scenario
- 7.7.2.5. Brazil Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.3. Argentina
- 7.7.3.1. Key Country Dynamics
- 7.7.3.2. Competitive Scenario
- 7.7.3.3. Regulatory Framework
- 7.7.3.4. Reimbursement scenario
- 7.7.3.5. Argentina Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8. Middle East & Africa
- 7.8.1. Middle East & Africa Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.2. South Africa
- 7.8.2.1. Key Country Dynamics
- 7.8.2.2. Competitive Scenario
- 7.8.2.3. Regulatory Framework
- 7.8.2.4. Reimbursement scenario
- 7.8.2.5. South Africa Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.3. Saudi Arabia
- 7.8.3.1. Key Country Dynamics
- 7.8.3.2. Competitive Scenario
- 7.8.3.3. Regulatory Framework
- 7.8.3.4. Reimbursement scenario
- 7.8.3.5. Saudi Arabia Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.4. UAE
- 7.8.4.1. Key Country Dynamics
- 7.8.4.2. Competitive Scenario
- 7.8.4.3. Regulatory Framework
- 7.8.4.4. Reimbursement scenario
- 7.8.4.5. UAE Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.5. Kuwait
- 7.8.5.1. Key Country Dynamics
- 7.8.5.2. Competitive Scenario
- 7.8.5.3. Regulatory Framework
- 7.8.5.4. Reimbursement scenario
- 7.8.5.5. Kuwait Autoinjectors Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- Chapter 8. Competitive Landscape
- 8.1. Market Participant Categorization
- 8.2. Company Market Share Analysis, 2025
- 8.3. Key Company Profiles
- 8.3.1. Eli Lilly
- 8.3.1.1. Company overview
- 8.3.1.2. Financial performance
- 8.3.1.3. Product benchmarking
- 8.3.1.4. Strategic initiatives
- 8.3.2. SHL Medical AG
- 8.3.2.1. Company overview
- 8.3.2.2. Financial performance
- 8.3.2.3. Product benchmarking
- 8.3.2.4. Strategic initiatives
- 8.3.3. AbbVie, Inc.
- 8.3.3.1. Company overview
- 8.3.3.2. Financial performance
- 8.3.3.3. Product benchmarking
- 8.3.3.4. Strategic initiatives
- 8.3.4. Amgen
- 8.3.4.1. Company overview
- 8.3.4.2. Financial performance
- 8.3.4.3. Product benchmarking
- 8.3.4.4. Strategic initiatives
- 8.3.5. Owen Mumford
- 8.3.5.1. Company overview
- 8.3.5.2. Financial performance
- 8.3.5.3. Product benchmarking
- 8.3.5.4. Strategic initiatives
- 8.3.6. Ypsomed
- 8.3.6.1. Company overview
- 8.3.6.2. Financial performance
- 8.3.6.3. Product benchmarking
- 8.3.6.4. Strategic initiatives
- 8.3.7. Teva Pharmaceutical
- 8.3.7.1. Company overview
- 8.3.7.2. Financial performance
- 8.3.7.3. Product benchmarking
- 8.3.7.4. Strategic initiatives
- 8.3.8. Biogen Idec
- 8.3.8.1. Company overview
- 8.3.8.2. Financial performance
- 8.3.8.3. Product benchmarking
- 8.3.8.4. Strategic initiatives
- 8.3.9. Mylan N.V.
- 8.3.9.1. Company overview
- 8.3.9.2. Financial performance
- 8.3.9.3. Product benchmarking
- 8.3.9.4. Strategic initiatives
- 8.3.10. Pfizer, Inc.
- 8.3.10.1. Company overview
- 8.3.10.2. Financial performance
- 8.3.10.3. Product benchmarking
- 8.3.10.4. Strategic initiatives
- 8.3.11. Sanofi
- 8.3.11.1. Company overview
- 8.3.11.2. Financial performance
- 8.3.11.3. Product benchmarking
- 8.3.11.4. Strategic initiatives
- 8.3.12. Gerresheimer AG
- 8.3.12.1. Company overview
- 8.3.12.2. Financial performance
- 8.3.12.3. Product benchmarking
- 8.3.12.4. Strategic initiatives
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
